newsfilter
← Earnings
Earnings Releases·

Annovis Bio — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Cash reserves declined to $2.8 million from $19.5 million at year-end 2025, while R&D expenses surged to $15.8 million for the quarter compared to $6.3 million in 2025; net loss per share improved to $0.22 from $0.37, though the nine-month net loss widened to $41.9 million from $19.0 million.
  • **Capital and Liquidity:** The company closed a public offering on November 6, 2026, raising approximately $21.0 million (including a $5.0 million contribution from the Chairman) to fund operations through the March 2027 DUET-AD data readout, resulting in a total accumulated deficit of $205.6 million.
  • **Clinical Progress:** The pivotal Phase 3 DUET-AD trial is fully enrolled with 862 patients, with the last patient visit scheduled for December 31, 2026, database lock on February 8, 2027, and top-line results expected in March 2027.
  • **Strategic Initiatives:** Annovis announced a partnership with Weave Bio to support NDA regulatory content and aims to prepare a significant portion of the New Drug Application for buntanetap prior to the 6-month data readout.
Company
ANNOVIS BIO INC
Sector
Healthcare
Industry
Biotechnology